

Attach
#8

INFORMATION DISCLOSURE CITATION PTO-1449				ATTORNEY'S DKT NO. 032775-090		APPLICATION NO. New 08/189,101	
				APPLICANT LEE et al.			
				FILING DATE Herewith		GROUP 1636 Unassigned	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
Tme	4,108,983	08/22/78	Wallack	424	89		
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes No	
Tme	0453242A1	10/23/91	Europe				
↓	0514603A1	11/25/92	Europe				
↓	90/09441	08/23/90	WO				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
Tme	G. Hashiro et al., "The Preferential Cytotoxicity of Reovirus for certain transformed cell lines", <i>Archives of Virology</i> 54(4):307-315 (1977)						
	J.E. Strong et al., "The Molecular Basis of Viral Oncolysis: Usurption of the Ras signaling Pathway by Reovirus", <i>The EMBO Journal</i> 17(12):3351-3362 (June 15 1998)						
	Tang et al., "Short communications: Recognition of the Epidermal Growth Factor Receptor by Reovirus" <i>Virology</i> 197:412-414 (1993)						
	Sharp et al., "Homologous regions of the α subunit of eukaryotic translational initiation factor 2 (eIF2 α) and the vaccinia virus K3L gene product interact with the same domain within the dsRNA-activated protein kinase (PKR)" <i>Eur. J. Biochem.</i> 250:85-91 (1997)						
	Randazzo et al., "Herpes Simplex virus 1716, and ICP 34.5 null mutant, is unable to replicate in CV-1 cells due to a translational block that can be overcome by coinfection with SV40" <i>J. of Gen. Virol.</i> 78:3333-3339 (1997)						
	He et al., "Suppression of the phenotype of γ 134.5- herpes simplex virus 1: Failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the α 47 Gene" <i>J. of Virol.</i> 71(8):6049-6054 (Aug. 1997)						
	Gale, Jr. et al., "Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein" <i>Virology</i> 230:217-227 (1997)						
↓	Kawagishi-Kobayashi et al., "Regulation of the protein kinase PKR by the vaccinia virus pseudosubstrate inhibitor K3L is dependent on residues conserved between the K3L protein and the pKR substrate 3IF2 α " <i>Mol. and Cell Biol.</i> 17(7):4146-4158 (1997)						
EXAMINER				DATE CONSIDERED			
Tanya McLeary				7/13/02			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION PTO-1449				ATTORNEY'S DKT NO. 032775-090		APPLICATION NO. New 89/989,161	
				APPLICANT LEE et al.			
				FILING DATE Herewith		GROUP Unassigned 1636	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
<i>Time</i> ↓	90/11765	10/18/90	WO				
	94/18992	09/01/94	WO				
	97/04805	02/13/97	WO				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>Time</i> ↓	Steele, T.A., and Cox, D. C., "Reovirus Type 3 Chemimmunotherapy of Murine Lymphoma is Abrogated by Cyclosporine," Cancer Biotherapy, 10(4): 307-315 (1995).						
	Cahill, M. A., et al., "Signalling pathways: Jack of all cascades," Current Biology, 6(1): 16-19 (1996).						
	Macara, I. G., et al., "The Ras superfamily of GTPases," The FASEB Journal, 10: 625-630 (1996).						
	Marshall, C. J., "Ras effectors," Current Opinion in Cell Biology, 8:197-204 (1996).						
	Strong, J. E. and Lee, P.W.K., "The v-erbB Oncogene Confers Enhanced Cellular Susceptibility to Reovirus Infection," J. of Virol. 70(1): 612-616 (1996).						
	Strong, J. E. et al., "Evidence That the Epidermal Growth Factor Receptor on Host Cells Confers Reovirus Infection Efficiency," Virol. 197:405-411 (1993).						
	Duncan, M. R., et al., "Differential Sensitivity of Normal and Transformed Human Cells to Reovirus Infection," J. of Virol. 28 (2): 444-449 (1978).						
	Soroceanu, L. et al., "Use of Genetically Engineered HSV-1 Viruses in Treatment of Malignant Intracerebral Gliomas," FASEB.J. 9(3): Abstract 812 p. A139 (1995).						
↓	Andreansky, S.S. et al., "The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors," Proc. Natl. Acad. Sci. USA 93:11313-11318 (1996).						
	Boviatsis, E.J., et al., "Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase," Gene Therapy 1:323-331 (1994).						
EXAMINER <i>Lenny A. McLeherry</i>				DATE CONSIDERED <i>9/13/02</i>			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION PTO-1449				ATTORNEY'S DKT NO. 032775-090		APPLICATION NO. New 09/989,161	
				APPLICANT LEE et al.			
				FILING DATE Herewith		GROUP Unassigned 1636	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
Tme	Taterka, J. et al., "Characterization of Cytotoxic Cells from Reovirus-Infected SCID Mice: Activated Cells Express Natural Killer-and Lymphokine-Activated Killer-Like Activity but Fail to Clear Infection," J. of Virol. 69 (6): 3910-3914 (1995).						
	Zhang, J.F., et al., "Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy," Proc. Natl. Acad. Sci. USA 93:4513-4518 (1996).						
	Chambers, R. et al., "Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma," Proc. Natl. Acad. Sci. USA 92:1411-1415 (1995).						
	Williams, M.E. et al., "Rejection of reovirus-treated L1210 leukemia cells by mice," Cancer Immunol. Immunother. 23:87-92 (1986).						
	Theiss, J.C. et al., "Effect of Reovirus Infection on Pulmonary Tumor Response to Urethan in Strain A Mice," J. Natl. Cancer Inst 61:131-134 (1978).						
	Kollermorgen, G.M. et al., "Immunotherapy of EL4 Lymphoma with Reovirus," Cancer Immunol. Immunother. 1:239-244 (1976).						
	Bryson, J.S. and Cox, D.C., "Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia," Cancer Immunol. Immunother. 26: 132-138 (1988).						
↓	Gentsch, J.R. and Pacitti, A.F., "Effect of Neuraminidase Treatment of Cells and Effect of Soluble Glycoproteins on Type 3						
EXAMINER	Tanya M. Kelen			DATE CONSIDERED 9/13/02			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION PTO-1449		ATTORNEY'S DKT NO. 032775-090		APPLICATION NO. New 89/989,101			
		APPLICANT LEE et al.					
		FILING DATE Herewith		GROUP Unassigned 1636			
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	FILING DATE		
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>TM</i> ↓	Strong, J.E. et al., "Evidence That the Epidermal Growth Factor Receptor on Host Cells confers Reovirus Infection Efficiency," Virology 197:405-411 (1993).						
↓	Barbacid, M., "ras Genes," Annu. Rev. Biochem. 56:779-827 (1987).						
↓	Hershey, J.W.B., "Translation Control in Mammalian Cells," Annu. Rev. Biochem. 60:717-755 (1991).						
EXAMINER	<i>Sam M. Kelley</i>			DATE CONSIDERED			
			<i>9/13/02</i>				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.